Surgicel
Phase 3Cell therapy
Surgicel is one of 13 small molecule programs targeting Knee Osteoarthritis. It is currently in Phase 3.
2
Indications
4
Total Trials
1
Active Trials
12
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
14 competitors in Knee Osteoarthritis
#DrugCompanyPhaseTrials
1Cymbalta
Jazz PharmaceuticalsApproved
Surgicel
PPeking University Third Hospital
Phase 3
Inulin and Sodium Chloride
BBlue Earth Diagnostics
Phase 2
Medrol
PfizerPreclinical
Allocetra
EEnlivex Therapeutics Ltd.
Phase 2
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Preclinical
Decadron
AAspen Global Incorporated
Preclinical
Solu-Medrol
MMassachusetts Eye and Ear Infirmary
Preclinical
Paracetamol
GSKPreclinical
Bee Venom Phonophoresis
SSinai University
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Heavy Menstrual Bleeding1 trial
Surgicel® & Endometrial Ablation in the Management of Perimenpausal Heavy Menstrual Bleeding
Unknown status·—·Phase 2·NCT03176992·240 enrolled
Endometrioma1 trial
Surgicel Reduces Ovarian Endometriomas Recurrence
Completed·—·Phase 2·NCT02947724·200 enrolled
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Surgicel. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Cell therapy[2]
- Highest Phase
- Phase 3[1]
- Company
- PPeking University Third Hospital